Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy (BY9010/M1-490)

Rhinitis, Allergic, Perennial Clinical Trial

Official title:

Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00806754
• Other study ID #: BY9010/M1-490
• Status: Completed
• Phase: Phase 4
• First received: December 10, 2008
• Last updated: November 22, 2016
• Start date: November 2006
• Est. completion date: August 2007

Study information

• Verified date: November 2016
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

• The primary objective of this study is to evaluate the efficacy of the concomitant administration of ciclesonide nasal spray and azelastine nasal spray versus ciclesonide nasal spray alone in patients (18 years or older) with perennial allergic rhinitis (PAR) not adequately controlled on an intranasal corticosteroid or antihistamine monotherapy

• The secondary objective is to investigate the safety of the concomitant administration of ciclesonide nasal spray and azelastine nasal spray

Recruitment information / eligibility

• Status: Completed
• Enrollment: 340
• Est. completion date: August 2007
• Est. primary completion date: May 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female, 18 years of age or older at the B0 Visit.

2. General good health, and free of any concomitant conditions or treatment that in the investigator's judgment could interfere with study conduct, influence the interpretation of study observations/results, or put the patient at increased risk during the trial.

3. A history of PAR for a minimum of two years immediately preceding the Screening Visit (B0). The PAR must have been of sufficient severity to require treatment(continuous or intermittent) in the past with intranasal corticosteroids and/or antihistamines and, in the investigator's judgment, experienced less than complete symptom alleviation on this prior therapy. In addition, the patient is again expected to require treatment throughout the study period.

4. A demonstrated sensitivity to at least one allergen known to induce PAR through a standard prick test within one year of study start. A positive test is defined as a wheal diameter at least 3 mm larger than the control (saline) wheal for the prick test. Documentation of a positive result within 12 months prior to the Screening Visit (B0) is acceptable.

5. Females of childbearing potential currently using contraception must continue to use a medically reliable method of contraception for the entire study duration(e.g. oral, injectable, trans-cutaneous or implantable contraceptives or intrauterine devices or double-barrier protection).Females who are not sexually active must agree to use double-barrier protection should they become active during the course of the study. Women of childbearing potential, or less than 1 year postmenopausal, will require a negative plasma pregnancy test at the Screening Visit (B0). Females will be considered to be of non-child-bearing potential and will not require a urine pregnancy test if at least one of the following apply:

• More than one year post-menopausal

• Had a hysterectomy

• Had bilateral ovariectomy or salpingectomy or tubal ligation

• Has congenital sterility

6. Patients on intranasal corticosteroids and antihistamines should be on a stable dose for at least 4 weeks.

7. Patients must complete a 24-hour reflective total nasal symptom assessment at the Screening Visit (B0) and score a total of 6 or greater (out of 12).

Exclusion Criteria:

1. Pregnancy, nursing, or plans to become pregnant or donate gametes (ova or sperm) for in vitro fertilization during the study period or for 30 days following the study period.

2. History of physical findings of nasal pathology, including nasal polyps (within the last 60 days) or other clinically significant respiratory tract malformations, recent nasal biopsy (within the last 60 days), nasal trauma, or surgery and atrophic rhinitis or rhinitis medicamentosa (within the last 60 days).

3. Participation in any investigational drug trial within the 30 days preceding the Screening Visit.

4. A known hypersensitivity to any intranasal corticosteroid, antihistamine or any of the excipients in the formulation.

5. History of a respiratory infection or disorder [including, but not limited to bronchitis, pneumonia, the common cold, acute or chronic sinusitis, flu, severe acute respiratory syndrome (SARS)] within the 14 days preceding the Screening Visit, or development of a respiratory infection during the Screening Period.

6. History of alcohol or drug abuse within the preceding two years.

7. History of a positive test for HIV, hepatitis B or hepatitis C.

8. Active asthma requiring treatment with inhaled or systemic corticosteroids and/or routine use of b-agonists; intermittent use of b-agonists is acceptable.

9. Use of any prohibited concomitant medications within the prescribed (per protocol) time since last dose period prior to the Screening Visit (B0) and during entire treatment duration.

10. Use of antibiotic therapy for acute conditions within 14 days prior to the Screening Visit (B0). Low doses of antibiotics taken for prophylaxis are permitted if the therapy was started prior to the Screening Visit AND is expected to continue throughout the trial.

11. Initiation of immunotherapy during the study period or dose escalation during the study period. However, initiation of immunotherapy 90 days or more prior to the Screening Visit AND use of a stable (maintenance) dose (30 days or more) may be considered for inclusion.

12. Non-vaccinated exposure to or active infection with, chickenpox or measles within the 21 days preceding the Screening Visit (B0).

13. Exposure to systemic corticosteroids for any indication, chronic or intermittent (e.g.: contact dermatitis), during the past 2 months, or presence of an underlying condition that can reasonably be expected to require treatment with corticosteroids during the course of the study.

14. Use of topical corticosteroids in concentrations in excess of 1% hydrocortisone for dermatological conditions during the past 1 month, or presence of an underlying condition that can reasonably be expected to require treatment with such preparations during the course of the study.

15. History of epilepsy or seizures (excluding febrile seizures).

16. History of coronary artery disease, uncontrolled hypertension, or other clinically significant cardiovascular disease.

17. Patients using combination treatment for allergic rhinitis (e.g. intranasal corticosteroid and antihistamine).

18. Have any of the following conditions that are judged by the investigator to be clinically significant and/or affect the subject's ability to participate in the clinical trial, might interfere with the study, require treatment or make implementation of the protocol or interpretation of the study results difficult:

• Impaired hepatic function including alcohol-related liver disease or cirrhosis;

• History of ocular disturbances e.g. glaucoma or posterior subcapsular cataracts;

• Any systemic infection;

• Hematological, hepatic, renal, endocrine (except for controlled diabetes mellitus or postmenopausal symptoms or hypothyroidism);· Gastrointestinal disease;

• Malignancy (excluding basal cell carcinoma).

19. Clinical site employees and their immediate relatives are excluded from study participation.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Rhinitis
• Rhinitis, Allergic
• Rhinitis, Allergic, Perennial

Intervention

Drug:
• Ciclesonide nasal spray + placebo Azelastine
Ciclesonide nasal spray 50 mcg + Placebo Azelastine
• Ciclesonide nasal spray + Azelastine
Ciclesonide nasal spray 50 mcg + Azelastine 137 mcg

Locations

Country	Name	City	State
United States	Altana/Nycomed	Ashland	Oregon
United States	Altana/Nycomed	Bethesda	Maryland
United States	Altana/Nycomed	Charleston	South Carolina
United States	Altana/Nycomed	Cincinnati	Ohio
United States	Altana/Nycomed	Colorado Springs	Colorado
United States	Altana/Nycomed	Dallas	Texas
United States	Altana/Nycomed	Denver	Colorado
United States	Altana/Nycomed	Encinitas	California
United States	Altana/Nycomed	Gainesville	Georgia
United States	Altana/Nycomed	Lakewood	Colorado
United States	Altana/Nycomed	Los Angeles	California
United States	Altana/Nycomed	Medford	Oregon
United States	Altana/Nycomed	Metairie	Louisiana
United States	Altana/Nycomed	Milwaukee	Wisconsin
United States	Altana/Nycomed	Mission Viejo	California
United States	Altana/Nycomed	Newport News	Virginia
United States	Altana/Nycomed	North Dartmouth	Massachusetts
United States	Altana/Nycomed	Novi	Michigan
United States	Altana/Nycomed	Overland Park	Kansas
United States	Altana/Nycomed	Papillion	Nebraska
United States	Altana/Nycomed	Pittsburgh	Pennsylvania
United States	Altana/Nycomed	Portland	Oregon
United States	Altana/Nycomed	Raleigh	North Carolina
United States	Altana/Nycomed	Richmond	Virginia
United States	Altana/Nycomed	Rolla	Missouri
United States	Altana/Nycomed	San Antonio	Texas
United States	Altana/Nycomed	San Diego	California
United States	Altana/Nycomed	San Jose	California
United States	Altana/Nycomed	Savannah	Georgia
United States	Altana/Nycomed	Shreveport	Louisiana
United States	Altana/Nycomed	Skillman	New Jersey
United States	Altana/Nycomed	South Burlington	Vermont
United States	Altana/Nycomed	Stockbridge	Georgia
United States	Altana/Nycomed	Sylvania	Ohio
United States	Altana/Nycomed	Upland	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Average of AM and PM patient-reported reflective Total Nasal Symptom Score (TNSS) over the four weeks of treatment		4 weeks	No
Secondary	Total physician-assessed nasal symptoms score (PNSS) at Endpoint		28 days	No

External Links

•   BY9010_M1-490 Synopsis